Besse-Hammer T - Search Results

1

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer.

Schuler M, Awada A, Harter P, Canon JL, Possinger K, Schmidt M, De Grève J, Neven P, Dirix L, Jonat W, Beckmann MW, Schütte J, Fasching PA, Gottschalk N, Besse-Hammer T, Fleischer F, Wind S, Uttenreuther-Fischer M, Piccart M, Harbeck N. Schuler M, et al. Breast Cancer Res Treat. 2012 Aug;134(3):1149-59. doi: 10.1007/s10549-012-2126-1. Epub 2012 Jul 5. Breast Cancer Res Treat. 2012. PMID: 22763464 Free PMC article. Clinical Trial.

2

Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors.

Awada AH, Dumez H, Hendlisz A, Wolter P, Besse-Hammer T, Uttenreuther-Fischer M, Stopfer P, Fleischer F, Piccart M, Schöffski P. Awada AH, et al. Invest New Drugs. 2013 Jun;31(3):734-41. doi: 10.1007/s10637-012-9880-0. Epub 2012 Nov 17. Invest New Drugs. 2013. PMID: 23161334 Free PMC article. Clinical Trial.

3

Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.

Awada A, Gil T, Whenham N, Van Hamme J, Besse-Hammer T, Brendel E, Delesen H, Joosten MC, Lathia CD, Loembé BA, Piccart-Ghebart M, Hendlisz A. Awada A, et al. J Clin Pharmacol. 2011 Dec;51(12):1674-84. doi: 10.1177/0091270010386226. Epub 2011 Jan 5. J Clin Pharmacol. 2011. PMID: 21209247 Clinical Trial.

4

A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors.

Raymond E, Alexandre J, Faivre S, Goldwasser F, Besse-Hammer T, Gianella-Borradori A, Jego V, Trandafir L, Rejeb N, Awada A. Raymond E, et al. Invest New Drugs. 2014 Feb;32(1):94-103. doi: 10.1007/s10637-013-9950-y. Epub 2013 Mar 29. Invest New Drugs. 2014. PMID: 23539344 Clinical Trial.

5

Circulating DNA in the neoadjuvant setting of early stage colon cancer.

Bregni G, Pretta A, Senti C, Acedo Reina E, Vandeputte C, Trevisi E, Gkolfakis P, Kehagias P, Deleporte A, Van Laethem JL, Vergauwe P, Van den Eynde M, Deboever G, Janssens J, Demolin G, Holbrechts S, Clausse M, De Grez T, Peeters M, D'Hondt L, Geboes K, Besse-Hammer T, Rothé F, Flamen P, Hendlisz A, Sclafani F. Bregni G, et al. Among authors: besse hammer t. Acta Oncol. 2022 Oct;61(10):1223-1229. doi: 10.1080/0284186X.2022.2101023. Epub 2022 Jul 22. Acta Oncol. 2022. PMID: 35866544

6

Tocilizumab-Induced Unexpected Increase of Several Inflammatory Cytokines in Critically Ill COVID-19 Patients: The Anti-Inflammatory Side of IL-6.

Ponthieux F, Dauby N, Maillart E, Fils JF, Smet J, Claus M, Besse-Hammer T, Bels D, Corazza F, Nagant C. Ponthieux F, et al. Among authors: besse hammer t. Viral Immunol. 2022 Jan-Feb;35(1):60-70. doi: 10.1089/vim.2021.0111. Epub 2022 Jan 27. Viral Immunol. 2022. PMID: 35085462 Clinical Trial.

7

Alteration of humoral, cellular and cytokine immune response to inactivated influenza vaccine in patients with Sickle Cell Disease.

Nagant C, Barbezange C, Dedeken L, Besse-Hammer T, Thomas I, Mahadeb B, Efira A, Ferster A, Corazza F. Nagant C, et al. PLoS One. 2019 Oct 10;14(10):e0223991. doi: 10.1371/journal.pone.0223991. eCollection 2019. PLoS One. 2019. PMID: 31600331 Free PMC article.

8

Pre-OPerative accelerated radiotherapy for early stage breast cancer patients (POPART): A feasibility study.

Mulliez T, Miedema G, Van Parijs H, Hottat N, Vassilieff M, Gillet E, Baeyens L, Voordeckers M, Coelmont J, Besse-Hammer T, Gevaert T, Nazac A, De Ridder M. Mulliez T, et al. Among authors: besse hammer t. Radiother Oncol. 2022 May;170:118-121. doi: 10.1016/j.radonc.2022.02.033. Epub 2022 Mar 4. Radiother Oncol. 2022. PMID: 35257850 Free article.

9

A score combining early detection of cytokines accurately predicts COVID-19 severity and intensive care unit transfer.

Nagant C, Ponthieux F, Smet J, Dauby N, Doyen V, Besse-Hammer T, De Bels D, Maillart E, Corazza F. Nagant C, et al. Among authors: besse hammer t. Int J Infect Dis. 2020 Dec;101:342-345. doi: 10.1016/j.ijid.2020.10.003. Epub 2020 Oct 9. Int J Infect Dis. 2020. PMID: 33039609 Free PMC article.

10

Value of diffusion-weighted MRI in predicting early response to neoadjuvant chemotherapy of breast cancer: comparison between ROI-ADC and whole-lesion-ADC measurements.

Hottat NA, Badr DA, Lecomte S, Besse-Hammer T, Jani JC, Cannie MM. Hottat NA, et al. Among authors: besse hammer t. Eur Radiol. 2022 Jun;32(6):4067-4078. doi: 10.1007/s00330-021-08462-z. Epub 2022 Jan 11. Eur Radiol. 2022. PMID: 35015127

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

19 results

Search Page